Mantle Cell Lymphoma | Tumor

Managing Mantle Cell Lymphoma (MCL) after Relapsed on First Treatment

An interview with Dr. Luhua (Michael) Wang, MD, Department of Lymphoma and Myeloma, Division of Cancer Medicine, MD Anderson Cancer Center

Keep Inspiring

Don’t let your disease define you

'The Future is Promising' For The Treatment of a Subtype of Non-Hodgkin Lymphoma

October 18th 2021, 1:00pm

Article

More selective BTK inhibitors like Brukinsa may give patients with mantle cell lymphoma who progressed on prior therapies another option with potentially fewer and more manageable side effects.

Mantle Cell Lymphoma Treatment in the Era of COVID-19

September 17th 2021, 1:00pm

Article

After determining an aggressive or non-aggressive treatment approach to mantle cell lymphoma, patients and clinicians must then discuss COVID-19 vaccine efficacy when determining a maintenance treatment strategy.

Tecartus for MCL: Expert Reflects After a Year Since FDA Approval

September 15th 2021, 9:00pm

Article

Tecartus was the first CAR-T cell therapy to be approved for the treatment of recurrent mantle cell lymphoma. Now, more than a year after its approval, a doctor discusses his experience prescribing the drug.

Third Dose of COVID-19 Vaccine May Increase Protection in Immunocompromised Patients

August 19th 2021, 9:00pm

Article

Patients who are immunocompromised, such as patients with blood cancers, may get the boosted immunity needed to reduce their risk for contracting COVID-19 and hospitalization for compilations related to the virus.

Expert Explains Prognosis Indicators, Treatment Plans in MCL

August 4th 2021, 7:00pm

Article

Some patients with mantle cell lymphoma can opt for a wait-and-watch approach, while others will need more aggressive treatment.

Patients With Blood Cancer Less Likely to Produce COVID-19 Antibodies After Vaccination

July 26th 2021, 1:00pm

Article

About 25% of patients with blood cancer did not produce antibodies after being vaccinated against COVID-19.

Choosing a BTK Inhibitor for MCL: Consider Side Effects and Insurance Coverage

July 16th 2021, 10:00pm

Article

When patients with mantle cell lymphoma are discussing the use of a BTK inhibitor, they must consider what their insurance will cover, as well as current health complications and potential side effects.

‘No One-Size-Fits-All’ First-Line Treatment for Mantle Cell Lymphoma

July 14th 2021, 6:00pm

Article

Patients can now prioritize whether durable responses to treatment or avoiding certain side effects are more valuable to them.

When MCL Relapses Early, Consider Different Treatment Options

July 13th 2021, 11:00pm

Article

Patients with mantle cell lymphoma whose disease relapses within a year and a half of transplant tend to have worse outcomes and may want to consider new treatment regimens.

FDA Fast Tracks Drug to Treat MCL

July 2nd 2021, 9:00pm

Article

The Food and Drug Administration granted a breakthrough therapy designation to a new drug that can be used to treat patients with mantle cell lymphoma.